Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

The majority of people with advanced EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line osimertinib ...

In the latest episode of Oncology Unscripted, Dr. John Marshall addresses critical issues concerning the dosing practices in oncology, particularly questioning the prevailing approach of using maximum ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report) today and set a price target ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

Panelist discusses how an early analysis of the mechanisms of acquired resistance to first-line treatment with amivantamab ...

Get detailed information on Osimertinib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...